BOSTON, MASS. -- The American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC) will host their annual International Conference on Molecular Targets and Cancer Therapeutics from Oct. 19-23, 2013, at the Hynes Convention Center in Boston, Mass.
The meeting, focusing on cancer drug development, draws nearly 3,000 attendees and gathers academics, scientists, and representatives from the pharmaceutical industry to discuss the effects new discoveries in cancer therapeutics and target selection have in molecular biology.
The online program can be found at http://www.
A press kit containing press releases and highlighted abstracts will be available Oct. 14.
Press conferences will take place at 10 a.m. ET, Sunday, Oct. 20, and Monday and Tuesday at 9 a.m. ET. New cancer research highlighted in the International Conference on Molecular Targets and Cancer Therapeutics 2013 press program includes:
- New markers for predicting response in BRAF-mutant melanoma;
- Markers for how lung cancer patients will respond to sorafenib;
- New method for evaluating the presence of the BRAF mutation;
- The continuing story of PARP inhibitors as they move to phase III trials;
- Possible new agent in head and neck cancers;
- New agent for treating resistance in gastrointestinal stromal tumors;
- Emerging therapies for BRAF melanoma and pancreatic and lung cancers; and
- New therapy for overcoming antiangiogenesis resistance.
Complimentary registration will be available to members of the media who provide press credentials.